The London-listed pharma company will stop sales of its Perseris medicine because it said the monthly injection is 'no longer financially viable'.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.